Recent developments highlight Mangoceuticals' expansion through intellectual property acquisitions, product launches in wellness and telehealth, and advances in antiviral research. The company has reported positive field study results for its poultry respiratory disease treatment and secured exclusive distribution agreements for skincare products.

• Mangoceuticals expanded its patent portfolio in nutraceuticals, enhancing its product offerings and intellectual property base [N1].
• The company reported 100% survival rates in field studies of MGX-0024 for poultry respiratory diseases, indicating progress in its antiviral research [N2].
• Mangoceuticals entered the wellness pouch market and appointed Tim Corkum to lead the new unit, signaling diversification into consumer wellness products [N3].
• It acquired intellectual property assets from Smokeless Technology Corp. to support expansion into the oral pouch delivery market [N4].
• The company secured exclusive rights for the plant-based nutriceutical Diabetinol® targeting pre-diabetes and weight management in the U.S. and Canada [N5].
• Mangoceuticals launched PeachesRx, a women's telehealth brand focused on wellness and GLP-1 treatments [N6].
• Research advances were made on respiratory illness prevention technologies targeting avian influenza, supporting the company's antiviral product pipeline [N7][N8].

Mangoceuticals has demonstrated progress in expanding its product portfolio through acquisitions and exclusive rights, including nutraceuticals and antiviral technologies. Its entry into the wellness pouch market and launch of a women's telehealth brand indicate strategic diversification. The company's related party pharmacy agreements provide a broad operational footprint across the U.S., supporting product distribution. Positive field study results for MGX-0024 in poultry respiratory diseases and ongoing research in respiratory illness prevention technologies highlight potential for future product development and market penetration.

The company faces significant risks due to its limited operating history, recurring net losses, and dependence on a related party pharmacy service provider for manufacturing and distribution. Regulatory challenges, potential product liability, and the need for additional capital to sustain operations pose material uncertainties. Market acceptance of new products and telehealth services is unproven, and the company is exposed to risks from counterfeit products, supply chain disruptions, and data security breaches. Failure to secure adequate financing could impair the company's ability to execute its business plan and maintain operations.

Mangoceuticals' moat is primarily based on its proprietary intellectual property acquisitions, exclusive rights to plant-based nutriceuticals, and its related party pharmacy service agreements that provide manufacturing and compounding capabilities across most U.S. states. Its integration of telehealth services and wellness product offerings, including a women's telehealth brand and wellness pouches, supports a diversified approach to market entry. However, the company's limited operating history, reliance on third-party pharmacy services, and early-stage status present challenges to establishing a durable competitive advantage.

• Reliance on Related Party Pharmacy Services: Mangoceuticals depends on Epiq Scripts, a related party, for manufacturing and compounding its products. Any operational, regulatory, or financial difficulties faced by Epiq Scripts could adversely affect Mangoceuticals' ability to supply products.
• Limited Operating History and Financial Losses: The company has a limited operating history with recurring net losses and an accumulated deficit. It may require additional capital to continue operations and fund growth initiatives.
• Regulatory and Product Liability Risks: Compounded products have not been FDA approved, exposing the company to potential litigation, regulatory scrutiny, and product liability claims.
• Market Acceptance and Competitive Risks: New product launches and telehealth services face uncertainties in customer acceptance, competitive pressures, and evolving industry standards.
• Supply Chain and Data Security Risks: Dependence on third-party transportation and data systems exposes the company to risks of disruptions, increased costs, and security breaches that could harm operations and reputation.

• Mangoceuticals, Inc. operates in the pharmaceutical and wellness product sectors with a focus on compounded pharmaceutical products and nutraceuticals.
• The company has a Master Services Agreement and related consulting agreements with Epiq Scripts, a related party pharmacy service provider licensed in 49 states and D.C., to provide pharmacy and compounding services.
• Mangoceuticals relies on Epiq Scripts for manufacture and compounding of its products, including the Mango product line and potential future men's wellness products.
• The company has a wholly-owned subsidiary, Mango & Peaches, which holds ownership of MangoRx Mexico and MangoRx UK, to segregate operations and liabilities.
• Mangoceuticals has entered into multiple intellectual property acquisitions and exclusive rights agreements, including for plant-based nutriceutical Diabetinol® targeting pre-diabetes and weight management in the U.S. and Canada.
• The company has launched a women's telehealth brand, PeachesRx, focusing on wellness and GLP-1 treatments.
• Mangoceuticals has expanded into the wellness pouch market and acquired intellectual property assets from Smokeless Technology Corp. to support this expansion.
• The company is advancing antiviral and respiratory illness prevention research targeting avian influenza and poultry respiratory diseases, reporting 100% survival rates in field studies of MGX-0024.
• Mangoceuticals has signed exclusive distribution agreements for its Dermytol® skincare line with Propre Energie.
• The company reported revenue of $456,021 and a net loss of $20,642,994 for the fiscal year ended December 31, 2025, with basic and diluted EPS of -$2.17 per share.
• As of December 31, 2025, Mangoceuticals had cash and cash equivalents of $1,486,338, current assets of $1,547,434, current liabilities of $890,568, a current ratio of 1.74, and a cash ratio of 1.67.
• The company has a limited operating history, launched its website in November 2022, and has generated limited revenues to date.
• Mangoceuticals faces risks related to reliance on third-party pharmacy services, regulatory compliance, product acceptance, and the need for additional capital to support operations.
• The company has entered into consulting agreements with key executives and service agreements with third parties for financial and compliance support.
• Mangoceuticals has experienced recurring net losses and an accumulated deficit, with capital resources not expected to be sufficient to fund operations for the next 12 months without additional financing.
• The company is subject to risks from counterfeit products, supply chain disruptions, data security breaches, and evolving privacy regulations.
• Mangoceuticals' business model includes product development, intellectual property acquisition, telehealth services, and distribution partnerships to expand its market presence.